Journal of Medicinal Chemistry · 2009 · 136 citations · 24 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAntiviral PharmacologyEnzyme InhibitionLead Compound DesignLigand-based DesignPotency Optimization3D Molecular ModelingAntiviral Drug DesignAntiviral Structure-activity RelationshipsChemical Library SynthesisDocking StudiesHigh-throughput Screening AssaysLead Compound ScreeningStructure-based Lead Discovery
We describe here the design, synthesis, molecular modeling, and biological evaluation of a series of small molecule, nonpeptide inhibitors of SARS-CoV PLpro. Our initial lead compound was identified via high-throughput screening of a diverse chemical library. We subsequently carried out structure-activity relationship studies and optimized the lead structure to potent inhibitors that have shown antiviral activity against SARS-CoV infected Vero E6 cells. Upon the basis of the X-ray crystal structure of inhibitor 24-bound to SARS-CoV PLpro, a drug design template was created. Our structure-based modification led to the design of a more potent inhibitor, 2 (enzyme IC(50) = 0.46 microM; antiviral EC(50) = 6 microM). Interestingly, its methylamine derivative, 49, displayed good enzyme inhibitory potency (IC(50) = 1.3 microM) and the most potent SARS antiviral activity (EC(50) = 5.2 microM) in the series. We have carried out computational docking studies and generated a predictive 3D-QSAR model for SARS-CoV PLpro inhibitors.
24
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Dean D. Erdman, Goldsmith Cs, Zaki et al. · New England Journal of Medicine · 2003 · 4.5K citations
Coronavirus as a possible cause of severe acute respiratory syndrome
ST Lai, Yi Guan, Lyc Yam et al. · The Lancet · 2003 · 3K citations · Full text
Bats Are Natural Reservoirs of SARS-Like Coronaviruses
Wendong Li, Meng Yu, Wuze Ren et al. · Science · 2005 · 2.7K citations · Full text
Veterinary Medicine, Infectious Diseases, Molecular Virology +14